<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264354</url>
  </required_header>
  <id_info>
    <org_study_id>CLV-412</org_study_id>
    <nct_id>NCT01264354</nct_id>
  </id_info>
  <brief_title>An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B</brief_title>
  <official_title>An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open study to evaluate the efficacy, safety of clevudine monotherapy or adefovir
      and clevudine combination in patients with chronic hepatitis B.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with HBV DNA levels ＜ 300 copies/mL</measure>
    <time_frame>24 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of HBV DNA form the baseline</measure>
    <time_frame>24week, 48week, 96week</time_frame>
    <description>(log copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBV DNA ＜ 300 copies/mL</measure>
    <time_frame>48week, 96week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ALT normalization</measure>
    <time_frame>24week, 48week, 96week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBeAg loss and/or seroconversion</measure>
    <time_frame>96 Week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clevudine 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clevudine 20mg+Adefovir dipivoxil 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clevudine 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine 30mg</intervention_name>
    <description>Clevudine 30mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Levovir 30mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine 20mg+Adefovir dipivoxil 10mg</intervention_name>
    <description>Clevudine 20mg+ Adefovir 10mg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Levovir 20mg+Adefovir 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine 20mg</intervention_name>
    <description>Clevudine 20mg</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Levovir 20mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is 18 years and older.

          -  Patient is documented to be HBsAg positive for &gt; 6 months.

          -  Patient is HBV DNA positive with DNA levels ≥ 1×10^5 copies/mL within 30days of
             baseline.

          -  Patient has ALT levels ≥ 1×ULN

          -  Patient who is able to give written informed consent prior to study start and to
             comply with the study requirements.

        Exclusion Criteria:

          -  Patient is currently receiving antiviral, immunomodulatory, cytotoxic or
             corticosteroid therapy.

          -  Patients previously treated with interferon, peg-interferon or other immunomodulatory
             within the previous 6 months.

          -  Patients previously treated with clevudine, lamivudine, adefovir, entecavir,
             telbivudine, Tenofovir or any other investigational nucleoside for HBV infection.

          -  Patient with clinical evidence of decompensated liver disease (Total bilirubin ＜
             2.0mg/dL, Prothrombin time ＜ 1.7(INR), Serum albumin≥3.5g/dL)

          -  Patient is coinfected with HCV, HDV or HIV.

          -  Patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.

          -  Patient with clinical evidence of hepatocellular carcinoma

          -  Patient with previous liver transplantation

          -  Patient is pregnant or breast-feeding.

          -  Patient has a clinically relevant history of abuse of alcohol or drugs.

          -  Patient has a significant immunocompromised, gastrointestinal, renal,

          -  hematological, psychiatric, bronchopulmonary, biliary diseases excluding asymptomatic
             GB stone, neurological, cardiac, oncologic(except HCC)or allergic disease or medical
             illness that in the investigator's opinion might interfere with therapy.

          -  Patient has creatinine clearance less than 60mL/min as estimated by the following
             formula: (140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dL]) [Note:
             multiply estimates by 0.85 for women]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2010</study_first_submitted>
  <study_first_submitted_qc>December 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <name_title>Byung Chul Yoo/Samsung Medical Center</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

